Related Experiment Video

Updated: Apr 26, 2026

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

14.4K

Different liposomal amphotericin B formulations for visceral leishmaniasis

Thomas P C Dorlo1, Manica Balasegaram2

  • 1Department of Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, Netherlands.

The Lancet. Global Health
|August 9, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
12:22

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

24.4K
In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

7.7K

Related Experiment Videos

Last Updated: Apr 26, 2026

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

14.4K
A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
12:22

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

24.4K
In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

7.7K

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

114
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
114

Articles linked to this work by shared authors, journal, and citation graph.

Using Stochastic Simulation-Estimation and Automated Model Development to Assess Power and Accuracy for Covariate Identification.

CPT: pharmacometrics & systems pharmacology·2026

Translational Pharmacokinetic-Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI-6148 for the Treatment of Cutaneous Leishmaniasis.

Clinical and translational science·2026

Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis.

The Journal of antimicrobial chemotherapy·2026

Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis.

International journal of antimicrobial agents·2026

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.

Lancet (London, England)·2025

Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing.

Clinical pharmacology and therapeutics·2025

Sustainability and adherence to behaviour change: a cross-sectional 3-year follow-up survey of an innovative Community Mobilisation and Community Incentivisation strategy (CoMIC trial) for child health in rural Pakistan.

The Lancet. Global health·2026

Drivers of adolescent pregnancy decline in five adolescent sexual and reproductive health and rights exemplar countries: a quantitative decomposition analysis.

The Lancet. Global health·2026

Integrating hypertension care into the existing HIV services package in Botswana (InterCARE): a pair-matched, cluster-randomised, type 2 hybrid effectiveness-implementation trial.

The Lancet. Global health·2026

Long-term mortality and risk of chronic kidney disease in children following severe malaria complicated by acute kidney injury: a prospective observational study.

The Lancet. Global health·2026

Causes of mortality and severe morbidity in young children in Sierra Leone: a prospective cohort study.

The Lancet. Global health·2026

8-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in children in Nepal (TyVOID): a prospective cohort follow-up study of the TyVAC Nepal randomised controlled trial.

The Lancet. Global health·2026

Blinatumomab administration in the outpatient setting: Safety and health care utilization.

Cancer·2026

Subcutaneous versus intravenous ultra-low dose rituximab in rheumatoid arthritis: a randomised controlled PK-PD non-inferiority trial.

Rheumatology (Oxford, England)·2026

The Role of γδ T Cells in Ischemic Stroke: Insights From the Perspective of the Brain-Gut Axis.

CNS neuroscience & therapeutics·2026

Macrophage migration inhibitory factor promotes immune evasion in multiple myeloma through myeloid-derived suppressor cell immunosuppression and major histocompatibility complex class I downregulation: implications for targeted therapy.

Haematologica·2026

Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications.

Haematologica·2026

Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin's lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial.

Haematologica·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us